Grading of prostatic adenocarcinoma: current state and prognostic implications

Area of Science:

• Urologic Oncology
• Cancer Pathology
• Prognostic Biomarkers

Background:

• The Gleason grading system is a critical prognostic tool in prostate cancer management.
• Despite its importance, the Gleason system has limitations and has undergone revisions.
• Accurate grading is essential for patient prognosis and therapeutic decisions.

Purpose of the Study:

• To review the current Gleason grading system for prostate cancer.
• To introduce a validated alternative grading system with five distinct Grade Groups.
• To discuss the implications of this new system for patient care.

Main Methods:

• Review of current prostate cancer grading guidelines, including the 2014 International Society of Urological Pathology Consensus Conference.
• Description of a new grading system based on modified Gleason scores, validated in multi-institutional studies.
• Explanation of the five Grade Groups (1-5) corresponding to specific Gleason score ranges.

Main Results:

• The Gleason grading system, while powerful, has persistent deficiencies impacting patient care.
• A new grading system categorizes prostate cancer into five Grade Groups (1-5) based on Gleason scores.
• Grade Group 1 corresponds to Gleason ≤6, Group 2 to 3+4=7, Group 3 to 4+3=7, Group 4 to Gleason 8, and Group 5 to Gleason 9-10.

Conclusions:

• The new 5-tier Grade Group system is simpler and more accurately reflects prostate cancer biology.
• The World Health Organization recommends using this new system alongside the traditional Gleason grading.
• This enhanced grading approach aims to improve prognostic accuracy and guide treatment strategies.